Holen Sie sich die Stockscreener-App
7.31
5.19%
-0.40
Handel nachbörslich:
7.33
0.02
+0.27%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SLDB?
Forum
Prognose
Aktiensplit
Solid Biosciences Inc Aktie (SLDB) Neueste Nachrichten
Friedreich Ataxia research spotlight as Solid Biosciences advances SGT-212 clinical trials - Traders Union
Options Flow: What analysts say about Solid Biosciences Inc stockExit Point & Technical Buy Zone Confirmations - baoquankhu1.vn
Solid Biosciences reports interim data from Duchenne gene therapy trial - Investing.com Australia
Solid Biosciences: Interim Data Lends Credibility For Q1 2026 Trial Start (NASDAQ:SLDB) - Seeking Alpha
Solid Biosciences says interim results reinforce confidence in SGT-003 potential - Yahoo Finance
SLDB: Wedbush Raises Price Target, Maintains Outperform Rating | - GuruFocus
Truist reiterates Buy on Solid Biosciences stock after trial data - Investing.com
Solid Biosciences (SLDB): Chardan Capital Maintains Buy Rating w - GuruFocus
Solid Biosciences Reports Encouraging Phase 1/2 Duchenne Data - TipRanks
Solid Bio’s SGT-003 Data Show DMD Gene Therapy Efficacy Without Liver Toxicity - Citeline News & Insights
Solid Biosciences Touts Encouraging Results For Duchenne Gene Therapy, FDA Talks Planned - Benzinga
Solid Biosciences (SLDB) Shares Drop After New Trial Data Releas - GuruFocus
Solid Biosciences reports interim data from Duchenne gene therapy trial By Investing.com - Investing.com Nigeria
Solid Biosciences (NASDAQ:SLDB) Shares Down 6.3%Time to Sell? - MarketBeat
Solid Biosciences shares fall after gene therapy trial data - Investing.com
Solid Bio falls amid new data for Duchenne drug (SLDB:NASDAQ) - Seeking Alpha
Solid Biosciences shares fall after gene therapy trial data By Investing.com - Investing.com Canada
Solid Biosciences (SLDB) Reveals Encouraging Interim Data from S - GuruFocus
Solid Biosciences Inc. unveils positive interim data from Duchenne gene therapy trial - Traders Union
Solid Biosciences Provides Interim Positive Clinical Update On Phase 1/2 Inspire Duchenne Trial - TradingView
Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial - GlobeNewswire
Wedbush Reiterates Outperform Rating for SLDB with $14 Price Tar - GuruFocus
Wedbush Reaffirms "Outperform" Rating for Solid Biosciences (NASDAQ:SLDB) - MarketBeat
Big Money Moves: Will Solid Biosciences Inc stock recover after earnings2026 Update & Long-Term Safe Investment Ideas - baoquankhu1.vn
Sarepta safety update on Elevidys boosts Regenxbio, hurts Solid Bio - MSN
Solid Biosciences Secures $240 Million in Private Placement - Global Legal Chronicle
Solid Biosciences (NASDAQ:SLDB) Reaches New 1-Year HighShould You Buy? - MarketBeat
Solid Biosciences secures $240M private placement funding By Investing.com - Investing.com Canada
Solid Biosciences Announces $240 Million Private Placement Financing - TipRanks
Solid Biosciences Raises $240 Million in Private Placement of Stock and Pre-Funded Warrants - TradingView
Solid Biosciences Inc. announced that it expects to receive $239.972139 million in funding - marketscreener.com
Solid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - Bitget
Solid Biosciences (SLDB) Announces $240M Private Placement - GuruFocus
Solid Biosciences Announces Oversubscribed $240 Million Private Placement - Bitget
Solid Biosciences announces $240 million private placement - MSN
Solid Biosciences secures $240M private placement funding - Investing.com India
Solid Biosciences Commences $240 Million Private Placement of Common Shares, Pre-Funded Warrants - marketscreener.com
Solid Biosciences stock jumps on $240M private placement - Investing.com
Solid Biosciences stock jumps on $240M private placement By Investing.com - Investing.com Nigeria
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
SLDB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Solid Biosciences (SLDB) Stock Price, News & Analysis - MarketBeat
Biotech Sector Sustains After-Hours Trading Gains - Intellectia AI
Solid Biosciences (SLDB) Projected to Post Earnings on Thursday - MarketBeat
Solid Biosciences Inc. (NASDAQ:SLDB) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Solid Biosciences Inc. sponsors international muscular dystrophy conference in Rome - Traders Union
SLDB SEC FilingsSolid Bioscience 10-K, 10-Q, 8-K Forms - Stock Titan
Solid Biosciences CTO Herzich sells $21k in shares By Investing.com - Investing.com South Africa
Solid Biosciences CEO Cumbo sells $96k in shares By Investing.com - Investing.com Canada
Solid Biosciences CTO Herzich sells $21k in shares - Investing.com India
Solid Biosciences COO Howton sells $43k in shares - Investing.com Australia
Patterns Watch: What are Solid Biosciences Incs earnings expectationsMarket Activity Recap & Safe Entry Trade Signal Reports - baoquankhu1.vn
David Howton Sells 7,469 Shares of Solid Biosciences (NASDAQ:SLDB) Stock - MarketBeat
Insider Selling: Solid Biosciences (NASDAQ:SLDB) CEO Sells $96,868.08 in Stock - MarketBeat
Solid Biosciences (NASDAQ:SLDB) Insider Jessie Hanrahan Sells 4,134 Shares - MarketBeat
Insider Selling: Solid Biosciences (NASDAQ:SLDB) Director Sells 2,658 Shares of Stock - MarketBeat
Solid Biosciences CFO Tan sells $31k in shares - Investing.com Nigeria
Solid Biosciences CFO Tan sells $31k in shares By Investing.com - Investing.com Nigeria
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):